Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
M.D. Anderson Cancer Center
Genentech, Inc.
National Cancer Institute (NCI)
The Methodist Hospital Research Institute
Bayer
Sotio Biotech Inc.
Dana-Farber Cancer Institute
Bayer
Mayo Clinic
Dragonfly Therapeutics
Merck Sharp & Dohme LLC
Alvotech Swiss AG
Dana-Farber Cancer Institute
Ohio State University Comprehensive Cancer Center
Emory University
Ohio State University Comprehensive Cancer Center
Tizona Therapeutics, Inc
Shanghai Henlius Biotech
Sandoz
City of Hope Medical Center
Mayo Clinic
University of Southern California
Novartis
Syntrix Biosystems, Inc.
Amgen
Memorial Sloan Kettering Cancer Center
Seattle Children's Hospital
Astellas Pharma Inc
Microbiotica Ltd
Asher Biotherapeutics, Inc.
Valo Therapeutics Oy
Formycon AG
MacroGenics
Toray Industries, Inc
Emory University
Herlev Hospital
Regeneron Pharmaceuticals
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Thomas Jefferson University
University of Pittsburgh
Turnstone Biologics, Corp.
GlaxoSmithKline
Turnstone Biologics, Corp.
Merck Sharp & Dohme LLC
University of Pennsylvania
Eli Lilly and Company
Vincerx Pharma, Inc.
Astellas Pharma Inc